UA102865C2 - Вспомогательные вещества для таблетирования на основе лактозы и целлюлозы - Google Patents

Вспомогательные вещества для таблетирования на основе лактозы и целлюлозы

Info

Publication number
UA102865C2
UA102865C2 UAA201104469A UAA201104469A UA102865C2 UA 102865 C2 UA102865 C2 UA 102865C2 UA A201104469 A UAA201104469 A UA A201104469A UA A201104469 A UAA201104469 A UA A201104469A UA 102865 C2 UA102865 C2 UA 102865C2
Authority
UA
Ukraine
Prior art keywords
lactose
cellulose
tableting aid
based tableting
aid
Prior art date
Application number
UAA201104469A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ойген Шварц
Гернот Варнке
Вєра Фіхтнер
Original Assignee
Молкерай Меггле Вассербург Гмбх Енд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41413349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA102865(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Молкерай Меггле Вассербург Гмбх Енд Ко. Кг filed Critical Молкерай Меггле Вассербург Гмбх Енд Ко. Кг
Publication of UA102865C2 publication Critical patent/UA102865C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

Изобретение касается способа изготовления гранулята на основе лактозы и целлюлозы (производного целлюлозы), гранулята, полученного указанным способом, и его применения как наполнителя для таблетирования.
UAA201104469A 2008-09-19 2009-09-21 Вспомогательные вещества для таблетирования на основе лактозы и целлюлозы UA102865C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008047910A DE102008047910A1 (de) 2008-09-19 2008-09-19 Tablettierhilfsstoff auf Laktose- und Cellulosebasis
PCT/EP2009/062203 WO2010031866A1 (de) 2008-09-19 2009-09-21 Tablettierhilfsstoff auf laktose- und cellulosebasis

Publications (1)

Publication Number Publication Date
UA102865C2 true UA102865C2 (ru) 2013-08-27

Family

ID=41413349

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201104469A UA102865C2 (ru) 2008-09-19 2009-09-21 Вспомогательные вещества для таблетирования на основе лактозы и целлюлозы

Country Status (13)

Country Link
US (1) US8663684B2 (ru)
EP (1) EP2344197B1 (ru)
KR (1) KR101661256B1 (ru)
CN (1) CN102202691B (ru)
BR (1) BRPI0918530B1 (ru)
CA (1) CA2737380C (ru)
DE (1) DE102008047910A1 (ru)
ES (1) ES2624231T3 (ru)
MX (1) MX337357B (ru)
NZ (1) NZ592331A (ru)
UA (1) UA102865C2 (ru)
WO (1) WO2010031866A1 (ru)
ZA (1) ZA201101982B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
CN102258495B (zh) * 2011-07-13 2013-01-30 石家庄四药有限公司 头孢丙烯片及其制备方法
BR112014015923B1 (pt) * 2011-12-27 2022-02-01 Amgen (Europe) GmbH Comprimidos revestidos de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metano-sulfoniletil]-4 - acetilaminoisoindolina-1,3-diona
HUE056810T2 (hu) 2012-11-02 2022-03-28 Murray & Poole Entpr Ltd Szív- és érrendszeri események kezelése és megelõzése kolchicin alkalmazásával
SG11201508571WA (en) 2013-04-16 2015-11-27 Murray And Poole Entpr Ltd Sustained-release formulations of colchicine and methods of using same
CN114504559B (zh) * 2022-03-01 2023-05-05 安徽山河药用辅料股份有限公司 一种药用辅料乳糖纤维素共处理物的制备方法
WO2024060048A1 (zh) * 2022-09-21 2024-03-28 浙江汉脉医药科技有限公司 糖类缓释组合物及其制备方法

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3045488A1 (de) 1980-12-03 1982-07-01 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von stabilisierten kallikreinhaltigen tabletten
DE3505433A1 (de) * 1985-02-16 1986-08-21 Basf Ag, 6700 Ludwigshafen Direkttablettierhilfsmittel
DE3506276C1 (de) 1985-02-22 1986-04-24 Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring Direkttablettiermittel
DD249186A1 (de) 1986-05-26 1987-09-02 Univ Halle Wittenberg Herstellungsverfahren einer neuen glibenclamid-arzneiform mit hoher bioverfuegbarkeit
ES2105368T3 (es) 1993-02-11 1997-10-16 Hoechst Ag Procedimiento para la fabricacion de componentes ceramicos de nitruro de silicio, densamente sinterizados, con alta resistencia mecanica.
CZ289649B6 (cs) 1994-07-22 2002-03-13 Krka, Tovarna Zdravil. P.O. Pevné lékové formy se spolehlivým uvolňováním aktivní sloľky alprazolamu a způsob jejich přípravy
DE19602757A1 (de) 1996-01-26 1997-07-31 Boehringer Mannheim Gmbh Feste Instant-Release-Darreichungsformen und Verfahren zu ihrer Herstellung
WO1997026865A1 (en) 1996-01-29 1997-07-31 Edward Mendell Co., Inc. Sustained release excipient
US5762961A (en) 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
DE19749897C1 (de) 1997-11-12 1999-08-26 Dds Drug Delivery Service Ges Zubereitung in Form eines Lipid-Hilfsstoff-Compounds und/oder eines Lipid-Wirkstoff-Compounds und Verfahren zu dessen Herstellung sowie dessen Verwendung zur Herstellung von Tabletten und/oder anderen größeren Matrixeinheiten
DE19651734C2 (de) 1996-12-12 1999-05-12 Dds Drug Delivery Service Ges Zubereitung in Form eines Polymer-Hilfsstoff-Compounds und/oder eines Polymer-Wirkstoff-Compounds und Verfahren zu dessen Herstellung sowie dessen Verwendung zur Herstellung von Tabletten und/oder anderen größeren Matrixeinheiten
AU732112B2 (en) * 1996-12-12 2001-04-12 Dds Drug Delivery Service Gesellschaft Zur Forderung Der Forschung In Pharmazeutischer Technologie Und Biopharmazie Mbh Formulation in the form of a matrix material-excipient compound, matrix material-active substance compound and/or matrix material-excipient-active substance compound, and processes for the preparation thereof and the use thereof for the preparation of tablets and/or other larger matrix units
CA2209868C (en) 1997-08-15 2001-08-14 Bernard Charles Sherman Pharmaceutical compositions comprising cefuroxime axetil
WO1999022738A1 (en) 1997-11-03 1999-05-14 Janssen Pharmaceutica N.V. Compositions of lipid lowering agents
US6168805B1 (en) 1998-05-07 2001-01-02 Endo Pharmaceuticals, Inc. Aqueous process for manufacturing paroxetine solid dispersions
EP1332757B1 (en) 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
CO5070643A1 (es) 1998-05-27 2001-08-28 Merck & Co Inc Formulacion en tabletas comprimidas
MA26693A1 (fr) 1998-09-28 2004-12-20 Glaxo Group Ltd Compositions pour administration par voie buccale
WO2000018375A1 (de) 1998-09-30 2000-04-06 Basf Aktiengesellschaft Verwendung von wasserlöslichen oder wasserdispergierbaren polyether-haltigen polymerisaten als überzugsmittel, bindemittel und/oder filmbildender hilfsstoff in pharmazeutischen darreichungsformen
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
CN1287769C (zh) 1998-11-20 2006-12-06 斯凯伊药品加拿大公司 可分散的磷脂稳定的微粒
US6716453B1 (en) * 1999-05-20 2004-04-06 Verion, Inc. Method for increasing the active loading of compressible composition forms
CZ20014379A3 (cs) 1999-06-11 2002-08-14 Ranbaxy Laboratories Limited Kompozice k maskování chuti a způsob její přípravy
DZ3179A1 (fr) 1999-08-03 2001-02-08 Lilly Icos Llc Compositions pharmaceutiques à base de beta-carboline.
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
DE50100265D1 (de) 2000-03-23 2003-07-03 Basf Drucksysteme Gmbh Verwendung von Pfropfcopolymeren zur Herstellung lasergravierbarer Reliefdruckelementen
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US20020001617A1 (en) 2000-05-26 2002-01-03 Chang-Hyun Lee Rapidly disintegrating tablet and process for the manufacture thereof
US6413590B1 (en) 2000-05-31 2002-07-02 Rexam Graphics Inc. Glossy ink jet medium
EP1295595A4 (en) 2000-06-30 2008-04-02 Astellas Pharma Inc TABLET RAPIDLY DISINTEGRATING IN THE MOUTH AND CORRESPONDING PRODUCTION PROCESS
ES2215696T3 (es) 2000-07-13 2004-10-16 Vitatene, S.A. Metodo para la produccion de una formulacion dispersable en agua que contiene carotenoides.
ES2292414T3 (es) 2000-07-27 2008-03-16 Roquette Freres Granulos a base de almidon y de lactosa.
IN192750B (ru) 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
US6610326B2 (en) * 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
SE0101329D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Pharmaceutical formulation
WO2002100407A1 (en) 2001-06-12 2002-12-19 Smartrix Technologies Inc. Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same
KR100906574B1 (ko) 2001-09-04 2009-07-10 다우 글로벌 테크놀로지스 인크. 유체를 고형 입자에 분산시키는 방법
WO2003020241A2 (en) 2001-09-05 2003-03-13 Vectura Limited Functional powders for oral delivery
DE10152351B4 (de) 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
US6753017B2 (en) 2001-11-07 2004-06-22 Jrs Pharma Lp Process for preparing dry extracts
US7179488B2 (en) * 2001-11-29 2007-02-20 Bob Sherwood Process for co-spray drying liquid herbal extracts with dry silicified MCC
EP1509204A4 (en) 2001-11-29 2005-07-13 Rettenmaier & Soehne Gmbh & Co AGGLOMERATED PARTICLES WITH AN ACTIVE SUBSTANCE PREPARED WITH MELTED MICROCRYSTALLINE CELLULOSE
WO2003048666A1 (en) 2001-11-29 2003-06-12 Penwest Pharmaceutical Company Process for co-spray drying liquid herbal extracts with dry silicified mcc
US20030206978A1 (en) * 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
AU2003222436B2 (en) 2002-01-10 2007-09-20 Lupin Limited Herbal composition for treating various disorders including psoriasis, a process for preparation thereof and method for treatment of such disorders
DE10207427A1 (de) 2002-02-21 2003-09-04 Basf Ag Schnelllöslicher Filmüberzug basierend auf Polyvinylalkohol-Polyether-Pfropfcopolymeren in Kombination mit Hydroxy-, Amid-, oder Esterfunktionen enthaltenden Komponenten
PT1578350E (pt) 2002-03-26 2009-08-27 Euro Celtique Sa Composições revestidas com geles de libertação constante
WO2003086343A2 (en) 2002-04-05 2003-10-23 Cadila Healthcare Limited Fast disintegrating oral dosage forms
MY128945A (en) * 2002-04-16 2007-03-30 Kowa Co Solid dispersion composition
EA007185B1 (ru) 2002-05-22 2006-08-25 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а
US20040037869A1 (en) 2002-08-16 2004-02-26 Douglas Cleverly Non-animal product containing veterinary formulations
GB0219516D0 (en) 2002-08-21 2002-10-02 Phoqus Ltd Fast dissolving and taste masked oral dosage form comprising sildenafil
US20040097484A1 (en) * 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
DE60216645T2 (de) 2002-12-19 2007-09-20 Council Of Scientific & Industrial Research Antiulcus pflanzenzusammensetzung(en)
MXPA05006802A (es) 2002-12-19 2005-09-08 Pharmacia Corp Formulacion no higroscopica que comprende un farmaco higroscopico.
AU2002353414A1 (en) 2002-12-30 2004-07-22 Council Of Scientific And Industrial Research Development of an anti-cough, anti-tussive and throat soothing herbal formulation
WO2004066982A1 (en) 2003-01-31 2004-08-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and processes for their preparation
WO2004082664A1 (en) 2003-03-21 2004-09-30 Ranbaxy Laboratories Limited Water-soluble tablets of metformin
WO2004089343A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Water soluble tablets
KR100503949B1 (ko) 2003-04-28 2005-07-26 주식회사유한양행 염산 온단세트론의 쓴맛을 효과적으로 은폐한 경구용 구강속붕해정 조성물
DE10319450A1 (de) 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
US20060115529A1 (en) 2003-05-07 2006-06-01 Seonghoon Jeong Fast-melting tablets having taste-masking and sustained release properties
WO2005007105A2 (en) 2003-07-10 2005-01-27 Smithkline Beecham Corporation Pharmaceutical compositions
TW200507882A (en) 2003-07-17 2005-03-01 Kyowa Hakko Kogyo Kk Solid formulations
WO2005009407A2 (en) 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
KR100604034B1 (ko) 2003-10-08 2006-07-24 주식회사유한양행 암로디핀 유리염기를 함유한 구강 속붕해정 및 그의 조성물
EP1680095A2 (en) 2003-11-03 2006-07-19 Zentiva, a.s. Valsartan containing formulation
WO2005051489A2 (en) 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Fast dissolving solid oral dosage forms of galanthamine
CA2551946A1 (en) 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galantamine
WO2005065662A1 (en) 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
US20060222677A1 (en) 2004-01-14 2006-10-05 Bianca Baroli Method of protecting sensitive molecules from a photo-polymerizing environment
WO2005082330A2 (en) 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Co-precipitated amorphous cefditoren pivoxil and dosage forms comprising the same
EP1720524A2 (en) 2004-02-26 2006-11-15 Ranbaxy Laboratories Limited Extended release tablets of clarithromycin
EP1765300A2 (en) 2004-06-10 2007-03-28 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
WO2005123041A1 (en) 2004-06-18 2005-12-29 Yuhan Corporation Oral dispersible tablet composition of amoxycillin and/or clavulanic acid comprising a surface-modified sodium bicarbonate
US20060127479A1 (en) * 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
US20060159747A1 (en) * 2004-12-17 2006-07-20 Boehringer Ingelheim International Gmbh Telmisartan and hydrochlorothiazide combination therapy
JP5224820B2 (ja) 2005-02-03 2013-07-03 ニコメド ファーマ エイエス カルシウム含有化合物を含む組成物の溶融造粒
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
GB0504203D0 (en) 2005-03-01 2005-04-06 Novartis Ag Organic compounds
JP2008536929A (ja) 2005-04-18 2008-09-11 ルビコン・リサーチ・ピーヴィーティー・エルティーディー 生体強化組成物
US20070014853A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Pharmaceutical dosage form containing novel pharmaceutical granulate
US20080200680A1 (en) 2005-10-17 2008-08-21 Cheng Brian K Polymorph Transformation of Zolpidem in Tablet Matrix
UA95093C2 (ru) 2005-12-07 2011-07-11 Нікомед Фарма Ас Способ получения кальциесодержащего соединения
CN101516356A (zh) * 2006-02-24 2009-08-26 特瓦制药工业有限公司 琥珀酸美托洛尔缓释片及其制备方法
WO2007096906A2 (en) 2006-02-27 2007-08-30 Panacea Biotec Ltd. Novel buccoadhesive compositions and process of preparation thereof
GB0610570D0 (en) 2006-05-27 2006-07-05 Pliva Istrazivanje I Razvoj D Novel formulation
CA2654402A1 (en) * 2006-06-01 2007-12-06 Adel Penhasi Multiple unit pharmaceutical formulation
JP5160423B2 (ja) 2006-07-19 2013-03-13 旭化成ケミカルズ株式会社 水易溶性薬物含有球状素顆粒の製造方法
CN100438917C (zh) * 2006-07-20 2008-12-03 山东聊城阿华制药有限公司 一种微晶纤维素乳糖的制备方法
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis

Also Published As

Publication number Publication date
MX337357B (es) 2016-02-29
EP2344197A1 (de) 2011-07-20
DE102008047910A8 (de) 2010-07-08
KR20110063549A (ko) 2011-06-10
BRPI0918530B1 (pt) 2019-06-04
DE102008047910A1 (de) 2010-03-25
US8663684B2 (en) 2014-03-04
CA2737380C (en) 2017-04-11
CN102202691A (zh) 2011-09-28
CA2737380A1 (en) 2010-03-25
ZA201101982B (en) 2011-11-30
KR101661256B1 (ko) 2016-09-30
WO2010031866A1 (de) 2010-03-25
US20110207826A1 (en) 2011-08-25
NZ592331A (en) 2012-10-26
CN102202691B (zh) 2014-03-26
EP2344197B1 (de) 2017-04-05
ES2624231T3 (es) 2017-07-13
MX2011002950A (es) 2011-08-03
BRPI0918530A2 (pt) 2015-12-08

Similar Documents

Publication Publication Date Title
MX2011008262A (es) Espiroamidas sustituidas como moduladores de b1r:.
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
CL2008001897A1 (es) Proceso para la preparacion de 3-halometil-1-metil-1h-pirazol, utiles como intermediario en la produccion de fungicidas; compuestos derivados de 3-halometil-1-metil-1h-pirazol.
MX337357B (es) Excipiente para tableteado a base de lactosa y celulosa.
MY197904A (en) Method for producing substituted 5-fluoro-1h-pyrazolopyridines
MX2018008597A (es) Composiciones inyectables de melfalan que comprenden un derivado de ciclodextrina y metodos de fabricacion y uso de las mismas.
UA86731C2 (ru) Делимая галеновая форма модифицированного высвобождения активного ингредиента
MY163339A (en) A method of producing ingenol-3-angelate
EP2130909A4 (en) METHOD OF PRODUCING TOOTH AND TOOTH PRODUCED BY THE METHOD
WO2010015657A3 (en) Alkoxypyrazoles and the process for their preparation
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
MX344246B (es) Procedimiento para la preparacion de cloruros de acido 5-fluoro-1-alquil-3-fluoroalquil-1h-pirazol-4-carboxilico.
UA101835C2 (ru) Способ получения производных 1-(2-галогенбифенил-4-ил)-циклопропанкарбоновой кислоты
MX2010004570A (es) Metodos para la produccion de sal.
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
MX362689B (es) Procedimiento de preparacion de derivados de acido 3,5-bis(fluoroalquil)pirazol-4-carboxilico y 3,5-bis(fluoroalquil) pirazoles.
TW201129620A (en) New formaldehyde scavengers
WO2007132354A3 (en) Process for preparing voriconazole, new polymorphic form of intermediate thereof, and uses thereof
UA106619C2 (ru) Способ получения производных 1- (2-галогенбифенил-4-ил) -циклопропанкарбоновои кислоты
SG10201805749QA (en) Substantially animal protein-free recombinant furin and methods for producing same
MY158910A (en) Surface modified silicic acid semi-gels
PL2300606T3 (pl) Sposób wytwarzania hydrolizatu kazeiny
WO2008075205A3 (en) Improved process for the preparation of voriconazole
EA201390336A1 (ru) Способ получения промежуточного соединения для синтеза лекарственного средства